Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 38, 2010, Pages 16554-16559

  Tsai, Yien Che ^a   Maditz, Rhyan ^a   Kuo, Chueh Ling ^b   Fishman, Paul S ^c,d   Shoemaker, Charles B ^b   Oyler, George A ^e   Weissman, Allan M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Veteran Affairs Maryland Health Care System   (United States)

^e SYNAPTIC RESEARCH LLC   (United States)

Author keywords

Botulinumtoxin; Clostridium; HECT domain; SNAP25; Synaptic transmission

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN E; PROTEASOME; RECOMBINANT PROTEIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UBIQUITIN PROTEIN LIGASE; BOTULINUM TOXIN; HYBRID PROTEIN; SNAP25 PROTEIN, MOUSE; UBIQUITIN;

ARTICLE; LIGHT CHAIN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION; AMINO ACID SEQUENCE; ANIMAL; BACTERIAL GENE; CELL LINE; CLOSTRIDIUM BOTULINUM TYPE A; CLOSTRIDIUM BOTULINUM TYPE E; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MOUSE; NERVE CELL; PATHOGENICITY; PHYSIOLOGY; TOXICITY;

CLOSTRIDIUM;

AMINO ACID SEQUENCE; ANIMALS; BOTULINUM TOXINS; BOTULINUM TOXINS, TYPE A; CELL LINE; CLOSTRIDIUM BOTULINUM TYPE A; CLOSTRIDIUM BOTULINUM TYPE E; GENES, BACTERIAL; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEURONS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOMBINANT FUSION PROTEINS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; UBIQUITIN;

EID: 78049242459     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1008302107     Document Type: Article

References (28)

1. Simpson LL (2000) Identification of the characteristics that underlie botulinum toxin potency: Implications for designing novel drugs. Biochimie 82:943-953.
2. Habermann E, Dreyer F (1986) Clostridial neurotoxins: Handling and action at the cellular and molecular level. Curr Top Microbiol Immunol 129:93-179.
3. Jahn R, Niemann H (1994) Molecular mechanisms of clostridial neurotoxins. Ann N Y Acad Sci 733:245-255.
4. Montecucco C, Schiavo G (1995) Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys 28:423-472.
5. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256:135-138.
6. Binz T, et al. (1994) Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 269:1617-1620.
7. Ferrer-Montiel AV, et al. (1998) The 26-mer peptide released from SNAP-25 cleavage by botulinum neurotoxin E inhibits vesicle docking. FEBS Lett 435:84-88.
8. Gutierrez LM, et al. (1997) A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells. J Biol Chem 272:2634-2639.
9. Raciborska DA, Charlton MP (1999) Retention of cleaved synaptosome-associated protein of 25 kDa (SNAP-25) in neuromuscular junctions: A new hypothesis to explain persistence of botulinum A poisoning. Can J Physiol Pharmacol 77:679-688.
10. Keller JE, Neale EA, Oyler G, Adler M (1999) Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 456:137-142.
11. Adler M, Keller JE, Sheridan RE, Deshpande SS (2001) Persistence of botulinum neurotoxinAdemonstrated by sequentialadministration of serotypesA and E in rat EDL muscle. Toxicon 39:233-243.
12. Fernández-Salas E, et al. (2004) Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci USA 101:3208-3213.
13. Deshaies RJ, Joazeiro CA (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78:399-434.
14. Varshavsky A (1996) The N-end rule: Functions, mysteries, uses. Proc Natl Acad Sci USA 93:12142-12149.
15. Xia ZP, Chen ZJ (2005) TRAF2:Adouble-edged sword? Sci STKE, 10.1126/stke.2722005pe7.
16. Chen ZJ (2005) Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 7:758-765.
17. Ivanov VN, Fodstad O, Ronai Z (2001) Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via up-regulation of p38, TNFalpha and suppression of NF-kappaB activities. Oncogene 20:2243-2253.
18. O'Sullivan GA, Mohammed N, Foran PG, Lawrence GW, Oliver Dolly J (1999) Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25. Identification of the minimal essential C-terminal residues. J Biol Chem 274:36897-36904.
19. Washbourne P, et al. (1999) Botulinum neurotoxin E-insensitive mutants of SNAP-25 fail to bind VAMP but support exocytosis. J Neurochem 73:2424-2433.
20. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
21. Lorick KL, et al. (1999) RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 96:11364-11369.
22. Foran PG, et al. (2003) Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 278:1363-1371.
23. Fernández-Salas E, HoH, Garay P, Steward LE,AokiKR(2004) Is the light chain subcellular localization an important factor in botulinum toxin duration of action? Mov Disord 19 (Suppl 8):S23-S34.
24. Alvarez SE, et al. (2010) Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465:1084-1088.
25. Sakamoto KM, et al. (2003) Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol Cell Proteomics 2:1350-1358.
26. Zhou P, Bogacki R, McReynolds L, Howley PM (2000) Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol Cell 6:751-756.
27. Rodriguez-Gonzalez A, et al. (2008) Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene 27:7201-7211.
28. Sakamoto KM, et al. (2001) Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA 98:8554-8559.